Wealthspring Capital LLC bought a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 408,950 shares of the company’s stock, valued at approximately $4,049,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Deltec Asset Management LLC acquired a new position in shares of Drugs Made In America Acquisition II during the 4th quarter valued at $495,000. Wolverine Asset Management LLC acquired a new position in shares of Drugs Made In America Acquisition II during the 4th quarter valued at $10,521,000. Finally, ABC Arbitrage SA acquired a new position in shares of Drugs Made In America Acquisition II during the 4th quarter valued at $396,000.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the stock. Weiss Ratings assumed coverage on shares of Drugs Made In America Acquisition II in a report on Monday, March 2nd. They issued a “sell (e)” rating on the stock. Wall Street Zen upgraded shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.
Drugs Made In America Acquisition II Stock Performance
Shares of DMII stock opened at $10.03 on Thursday. Drugs Made In America Acquisition II Corp. has a 12 month low of $9.86 and a 12 month high of $10.03. The business has a fifty day moving average price of $9.99.
About Drugs Made In America Acquisition II
Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank?check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.
The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply?chain resiliency and related healthcare operations in the United States.
Further Reading
- Five stocks we like better than Drugs Made In America Acquisition II
- Oklo Stock Could Be Ready for Another Massive Run
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
Want to see what other hedge funds are holding DMII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Free Report).
Receive News & Ratings for Drugs Made In America Acquisition II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition II and related companies with MarketBeat.com's FREE daily email newsletter.
